HALIFAX, Nova Scotia, Canada (September 7, 2005) – Origin BioMedicinals Inc. announced today that it has received US FDA registration for its pain relief product NEURAGEN® PN. NEURAGEN® PN is a homeopathic blend of its popular Canadian product – NEURAGEN® RL. Neuragen® PN consists of a proprietary blend of botanical essential oil compounds, which was developed by two large US chronic pain centers in the early 1990’s.

Origin BioMedicinals’ product is used today by health practitioners for the treatment of diabetic peripheral neuropathy, post-shingles pain, fibromyalgia, spinal compression pain and other chronic nerve pain. NEURAGEN® is a topical oil that can be used only as needed for these painful conditions, providing greater ease of use and less side effects than prescription drugs. NEURAGEN® PN now contains St. John’s Wort (Hypericum) as a homeopathic ingredient for added effectiveness.

Two previous trials were conducted for NEURAGEN®. The first trial was for diabetic peripheral neuropathy, where 70% of 29 patients noted improvement in pain, usually within minutes of applying NEURAGEN® topically. Of these, most patients noted a remarkable 50-100% improvement in pain. Efficacy was measured by reduction in pain intensity over the first six hours.

This rate of efficacy is comparable or better than the prescribed pharmaceutical drugs for neuropathic pain, but without any side effects. Reported quality of life benefits during the study also included improved joint flexibility, decreased cramping and improved balance, as well as improvement in sleep, work ability, social life, energy and less depression. A second multi-center trial for post-shingles pain, similar results were reported where 68% of 30 patients experienced substantial pain relief ranging from 2-10 hours, and occurring within 5-15 minutes.